KURA News and Press, Kura Oncology Inc. From 09/06/21

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Kura Oncology, Inc. (KURA) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 ET Company Participants Pete De Spain - VP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Marc Grasso - CFO & Chief Business Officer Conference Call Participants Jonathan Cha...

Image source: The Motley Fool. Kura Oncology, inc (NASDAQ: KURA) Q2 2021 Earnings Call Aug 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Kura Oncology, inc (KURA) Q2 2021 Earnings Call Transcript

Kura Oncology (NASDAQ:KURA): Q2 GAAP EPS of -$0.51 misses by $0.02. Cash, cash equivalents and short-term investments totaled $567.5 million as of June 30, 2021, compared with $633.3 million as of December 31, 2020.  Management expects that current cash, cash equivalents and short-term i...

– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC – – KO-2806 nominated as lead devel...

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conf...

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after ...

Kura Oncology (NASDAQ:KURA) announces the appointment of industry veteran Helen Collins to the company's board of directors. Collins joins the Kura board of directors with more than 25 years of medical experience. Most recently, she served as Executive Vice President and Chief ...